Do you want to read an article? Please log in or register.
Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
Tuberculosis
RECOMMENDED
Related content
RECOMMENDED
Tuberculosis
Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling
Lancet Infect Dis.
Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ
doi: 10.1016/S1473-3099(19)30307-X.
RECOMMENDED
Tuberculosis
Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis
Am J Respir Crit Care Med.
Dheda K, Lenders L, Magombedze G, Srivastava S, Raj P, Arning E, Ashcraft P, Bottiglieri T, Wainwright H, Pennel T, Linegar A, Moodley L, Pooran A, Pasipanodya JG, Sirgel FA, van Helden PD, Wakeland E, Warren RM, Gumbo T
doi: 10.1164/rccm.
RECOMMENDED
Tuberculosis
Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review
Eur Respir J.
Law S, Daftary A, O'Donnell M, Padayatchi N, Calzavara L, Menzies D
doi: 10.1183/13993003.
RECOMMENDED
Tuberculosis
Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet.
Bisson GP, Bastos M, Campbell JR, Bang D, Brust JC, Isaakadis P, Lange C, Menzies D, Migliori GB, Pape JW, Palmero D, Baghei P, Tabarsi P, Viiklepp P, Vilbrun S, Walsh J, Marks SM
doi: 10.1016/S0140-6736(20)31316-7.
Respiratory Tract Infection
Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015
Lancet Infect Dis.
GBD 2015 LRI Collaborators
doi: 10.1016/S1473-
RECOMMENDED
Tuberculosis
Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Glob Health.
Marx FM, Cohen T, Menzies NA, Salomon JA, Theron G, Yaesoubi R
doi: 10.1016/S2214-109X(20)30227-8.
RECOMMENDED
Tuberculosis
Management of drug-resistant tuberculosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet.
Lange C, Dheda K, Chesov D, Mandalakas AM, Udwadia Z, Horsburgh CR Jr
doi: 10.1016/S0140-6736(19)31882-3.
Clinical Management of Multidrug-resistant Tuberculosis in 16 European Countries
Am J Respir Crit Care Med.
Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Magis-Escurra C, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C
doi: 10.1164/rccm.
RECOMMENDED
Tuberculosis
Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
N Engl J Med.
Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J, McHugh TD, Wills G, Bateson A, Hunt R, Van Niekerk C, Li M, Olugbosi M, Spigelman M
doi: 10.1056/NEJMoa1901814.